Serinus Biosciences
Serinus Biosciences is an artificial intelligence company focused on designing cancer drug combinations[1]. The platform uses rational design methodology to create combination therapies intended to override treatment resistance[1]. Founded in 2022[3], the company is based in New York City, NY[2]. Serinus Biosciences participated in Y Combinator's Summer 2022 batch[3].
About
- Serinus Biosciences is tackling one of the toughest problems in cancer treatment: creating combination therapies to override treatment resistance. We leverage cutting edge technology to design a fully explainable AI platform primed with decades of system biology knowledge. Uniquely powered for biological inference, our AI engine uncovers how cancer cells evolve treatment resistance and identifies molecules to overcome resistance escape routes. We design combinations that are safer, more effective, and can get to patients quickly. Founded by MIT PhDs and supported by a scientific advisory board of top academics from the Broad Institute, Dana-Farber, and UCSD, Serinus is powered by Y Combinator and other top investors to revolutionize precision medicine.[8]
Something wrong or missing? Send a correction. Fixed within 24 hours.